Exacerbation of clinical manifestations of bullous pemphigoid after treatment with dupilumab-Reference-Cited by-同舟云学术

Exacerbation of clinical manifestations of bullous pemphigoid after treatment with dupilumab

Published:2023-11-27 Issue: Volume: Page:
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:

Author:

Mariotti Elena Biancamaria¹^ORCID,Corrà Alberto¹^ORCID,Aimo Cristina¹,Ruffo di Calabria Valentina¹,Quintarelli Lavinia²,Verdelli Alice²,Caproni Marzia²

Affiliation:

1. Section of Dermatology, Department of Health Sciences, University of Florence , Florence , Italy

2. Rare Diseases Unit, Section of Dermatology, Department of Health Sciences, USL Toscana Centre, European Reference Network-Skin Member, University of Florence , Florence , Italy

Abstract

The article presents an adverse event that occurred after the induction phase of dupilumab, administered in another country to a patient affected by bullous pemphigoid.

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llad412/55431478/llad412.pdf

Reference7 articles.

1. Dupilumab for the treatment of adult atopic dermatitis in special populations;Patruno;J Dermatolog Treat,2022

2. Dupilumab treatment in children aged 6–11 years with atopic dermatitis: a multicentre, real-life study;Napolitano;Paediatr Drugs,2022

3. Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review;Su;Dermatology,2023

4. New onset atopic dermatitis and psoriasis in the same patients under biologic treatments: the role of systemic treatments as a possible trigger;Paolino;Dermatol Ther,2022

5. Evaluation of dupilumab in patients with bullous pemphigoid;Zhao;JAMA Dermatol,2023